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Available online 26 May 2016Prostate cancer is the second leading cancer inmenworld-wide. Due to its heterogeneous nature, a considerable
amount of research effort has been dedicated in identifying effective clinical biomarkers with a focus on proteins,
messenger RNA andmicroRNAs [1]. However, there is limited data on the role and expression of long noncoding
RNAs (lncRNAs) in prostate cancer exosomes [2]. This array dataset which is linked to our publication describes
the proﬁling of human lncRNAs in prostate cancer and their exosomes from ﬁve different cell lines [3]. From this
dataset, we identiﬁed a list of statistically signiﬁcant prostate cancer lncRNAs which are differentially expressed
in the exosomes compared to their parent cell lines. This dataset has been deposited into Gene Expression
Omnibus (GSE81034).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under2. Experimental design, materials and methods
The experiment design and data analysis pipeline is shown in Fig. 1.
In the following sections, we review the experiment design, quality as-
sessment of the prepared data and the analysis pipeline for this dataset.
3. Tissue culture of prostate cancer cell lines
Prostate cancer cell lines, LNCaP, PC3, and DU145 were cultured in
RPMI medium, VCaP cells were grown in F12:DMEM and PNT2 cell
lines in deﬁned KSFM (Invitrogen, USA). All cells were incubated at
37 °C in 5% CO2, and supplementedwith 1% v/v penicillin, streptomycin,
glutamine and 10% v/v fetal calf serum. As Fetal Calf Serum contains
exosomes of bovine origin all media were depleted of these bovine
exosomes. To remove bovine exosomes, we utilized the ultracentrifuga-
tion protocol devised by Théry, C. et al. [2].
4. Isolation of exosomes using ultracentrifugation
Harvested culture was centrifuged twice, ﬁrstly at 500g for 30 min,
and then at 2000g for 10 min to remove dead cells and any debris. The
resulting supernatant was then centrifuged at 10,000g for 30 min to
separate micro-particles and other proteins from the exosomes. The su-
pernatantwas collected from this step and then centrifuged at 100,000g
for 120 min to obtain an exosomal pellet. The supernatant was
discarded, and the pellet retained. The exosomal pellet was then re-
suspended in PBS and centrifuged at 100,000g for 90min. This resulting
pellet contains the exosomes which was subjected to RNA isolation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2.A) Box plot representing intensities distributions. B) A representative scatter plot of
PC3 exosomes vs PC3 cell. The green lines indicate fold change lines whereby the default
fold change value is 2.0.
Fig. 1. Experimental overview of the project and the data processing pipeline. Four
difference prostate cancer cell lines were grown and the media harvested from these
cell lines were used to isolate exosomes. Total RNA was then extracted from both
cellular and exosomal sources. Integrity and concentration of RNA were assessed after
RNA extraction and prior to sample labeling. Agilent low RNA input linear ampliﬁcation
kit PLUS was used for sample ampliﬁcation and labeling. After washing, slides were
scanned with the Agilent DNA Microarray Scanner. Data was extracted using Agilent
feature extraction software. Normalization and further data analysis was performed
using GeneSpring v11.5.1 software.
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RNAzol RT (Molecular Research Center, USA) was used to extract
total RNA from both cellular and exosomal sources [4]. 1 mL of RNAzol
was added to the exosomal pellet and homogenised using a blunt nee-
dle syringe. This homogenate is added to 0.4 mL of water and left to in-
cubate on ice for up to 15min. The sample was then centrifuged at 4 °C,
at 12,000g for 15 min. 1 mL of the resulting supernatant was removed
and puriﬁcation performed via the addition of 5 μL of 4-bromoanisole.
The sample was incubated for 3–4 min, and centrifuged at 12,000g, 4 °
C, for 10min. The supernatantwas removed from the sample, and 1 vol-
umeof isopropanolwas addedwith 5 μL of glycogen (25mg/mL) to pre-
cipitate the RNA. This mixture was then incubate on dry ice for 15 min
followed by centrifugation at 12,000g, 4 °C, for 10 min. The resultingRNA pellet was then washed twice in 75% ethanol and centrifuge at
8000g for 5 min to collect the pellet. After discarding the supernatant,
the exosomal RNA pellet was solubilized with the addition of 50 μL of
RNA/DNA free water.
6. Preparation of lncRNAs for hybridization to Agilent arrays
RNA Integrity and concentration was assessed post RNA extraction
and prior to sample labeling. The sample RNA integrity number (RIN)
was determined using a Bioanalyzer 2100 to assess RNA quality. RNA
concentration, protein contamination and organic compound contami-
nation was measured for all samples using the NanoDrop ND-1000.
Agilent Low RNA Input Linear Ampliﬁcation Kit PLUS was used for
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the Agilent SureHyb Hybridization Chambers. The labeled cRNAs were
hybridized onto the Human lncRNA array v2.0 (8 × 60 K, Arraystar)
for the global proﬁling of 33,045 human lncRNAs. The lncRNAs in this
array were collected from databases such as RefSeq, UCSC Known
genes, and Ensembl. After washing the array slides, they were scanned
using the Agilent Scanner G2505B. Agilent Feature Extraction software
(version 10.7.3.1) was then used to analyze the acquired array images
for 1) outlier analysis, 2) net signal statistics analysis, 3) local back-
ground statistical analysis, and 4) reproducibility analysis of the signals.
7. Data normalization and analysis
Quantile normalization was performed using the GeneSpring GX
v11.5.1 software package (Agilent Technologies). After quantile normal-
ization of the raw data, lncRNAs of which 6 out of 10 samples had ﬂags
in Present or Marginal (“All Targets Value”) were adjusted by CombatFig. 3. A heatmap representing the differential lncRNA expression in the parental prostate
cancer cell lineages and their exosomes. “red” indicates high relative expression and
“blue” indicates low relative expression.program to remove batch effects and were chosen for differentially
expressed LncRNA screening. In the next step, quality assessment of
lncRNA data for the different cell lines was performed by 1) investigat-
ing the box plot of the normalized intensity values to compare
the distributions of intensities among different samples (Fig. 2A) and
2) inspecting the scatter plot of the log2 scaled values of the averaged
normalized signal values of the exosomes versus the cells of each cell
line to assess the lncRNA expression variations (Fig. 2B). To identify
differentially expressed lncRNA, a fold change ﬁltering with a threshold
of fold change ≥2.0was performed. Generation of the heatmaps and the
hierarchical cluster analysis was performed using Agilent GeneSpring
GX v11.5.1.
8. Discussion
Our dataset represents a novel categorization of lncRNA levels in
prostate cancer exosome and their parental lineages. We have proﬁled
four common prostate cancer cell lines and compared these to the nor-
mal PNT2 cells. Our array data suggested that lncRNAs are present in
abundance in both healthy and prostate cancer exosomes. We normal-
ized the data using quantile normalization and then ﬁlter the data by
using a two-fold threshold. From this the dataset, we also identiﬁed
26 down-regulated and 19 upregulated lncRNAs which were common
to these exosomes. Furthermore, these exosomal lncRNAs appeared to
be enriched for miRNA seeds with a preference for miR-17, miR-18a,
miR-20a, miR-93, miR-106b and the let-7 family members [3]. With
these observation, we put forward the notion that lncRNAs can act as
miRNA sponges and their speciﬁc enrichment in exosomes is an impor-
tant step in prostate cancer carcinogenesis. The heat maps clearly
showed the similarities and differences in the lncRNA expression be-
tween cancer exosomes/cells versus the normal exosomes/cells
(Fig. 3). Although there have been many studies using small ncRNAs
for cancer diagnosis [1], with this dataset, it may be possible to discover
potential exosomal lncRNAs which can be utilized for prostate cancer
diagnosis.
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